Azitra is trading 6.67% down now at $0.17, with no fresh company-specific catalyst identified for August 31, 2026.

  • Latest notable announcements were second-quarter results on August 12 and restored NYSE American compliance on August 21; both predated this move.
  • The decline appears to reflect weak, volatile biotech sentiment and momentum after several consecutive advances.
  • Broader indexes are mixed and provide no strong confirmation; confidence remains low.